Dr. David F. Ransohoff

Dr. David F. Ransohoff's AcademicInfluence.com Rankings

Philosophy

#5877

World Rank

#8801

Historical Rank

Logic

#3084

World Rank

#4192

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Dr. David F. Ransohoff's Degrees

Doctorate Medicine University of North Carolina at Chapel Hill

Why Is Dr. David F. Ransohoff Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Dr. David F. Ransohoff's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration (2015) (2626)
Dysplasia in inflammatory bowel disease: standardized classification with provisional clinical applications. (1983) (1775)
Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. (1978) (1703)
Multitarget stool DNA testing for colorectal-cancer screening. (2014) (1276)
Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. (2000) (1076)
Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma (2009) (977)
Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. (2004) (805)
Prospective evaluation of methylated SEPT9 in plasma for detection of asymptomatic colorectal cancer (2013) (593)
The natural history of silent gallstones: the innocent gallstone is not a myth. (1982) (569)
Rules of evidence for cancer molecular-marker discovery and validation (2004) (524)
Bias as a threat to the validity of cancer molecular-marker research (2005) (501)
Gastroesophageal reflux, barrett esophagus, and esophageal cancer: scientific review. (2002) (500)
Treatment adherence and risk of death after a myocardial infarction (1990) (481)
Nonpolypoid neoplastic lesions of the colorectal mucosa. (2008) (477)
European guidelines for quality assurance in colorectal cancer screening and diagnosis: Overview and introduction to the full Supplement publication (2012) (469)
Addressing overdiagnosis and overtreatment in cancer: a prescription for change. (2014) (414)
Adverse Events After Outpatient Colonoscopy in the Medicare Population (2009) (411)
Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. (2007) (409)
Results of screening colonoscopy among persons 40 to 49 years of age. (2002) (389)
Proteogenomic Analysis of Human Colon Cancer Reveals New Therapeutic Opportunities (2019) (366)
Are Physicians Doing Too Much Colonoscopy? A National Survey of Colorectal Surveillance after Polypectomy (2004) (340)
Standardized colonoscopy reporting and data system: report of the Quality Assurance Task Group of the National Colorectal Cancer Roundtable. (2007) (291)
Lessons from controversy: ovarian cancer screening and serum proteomics. (2005) (270)
Five-Year risk of colorectal neoplasia after negative screening colonoscopy (2008) (252)
Prophylactic cholecystectomy or expectant management for silent gallstones. A decision analysis to assess survival. (1983) (249)
National Institutes of Health State-of-the-Science Conference Statement: ERCP for diagnosis and therapy, January 14-16, 2002. (2002) (246)
Bone-density testing interval and transition to osteoporosis in older women. (2012) (227)
CLINICAL GUIDELINE: PART II: Screening for Colorectal Cancer with the Fecal Occult Blood Test: A Background Paper (1997) (205)
Screening for colorectal cancer. (1991) (199)
The Scientific Foundation for Personal Genomics: Recommendations from a National Institutes of Health–Centers for Disease Control and Prevention Multidisciplinary Workshop (2009) (196)
A National Survey of Primary Care Physicians' Methods for Screening for Fecal Occult Blood (2005) (190)
Principles of cancer screening: lessons from history and study design issues. (2010) (186)
Sources of bias in specimens for research about molecular markers for cancer. (2010) (180)
International variation in screening mammography interpretations in community-based programs. (2003) (179)
A Framework for Evaluating Biomarkers for Early Detection: Validation of Biomarker Panels for Ovarian Cancer (2011) (169)
Using Risk for Advanced Proximal Colonic Neoplasia To Tailor Endoscopic Screening for Colorectal Cancer (2003) (161)
How to improve reliability and efficiency of research about molecular markers: roles of phases, guidelines, and study design. (2007) (160)
Proteogenomic Landscape of Breast Cancer Tumorigenesis and Targeted Therapy (2020) (156)
How to decide whether a clinical practice guideline is trustworthy. (2013) (147)
Improving Colorectal Cancer Screening in Primary Care Practice: Innovative Strategies and Future Directions (2007) (144)
Variation in polyp detection rates at screening colonoscopy. (2009) (140)
Why is prostate cancer screening so common when the evidence is so uncertain? A system without negative feedback. (2002) (134)
Endoscopic detection of proximal serrated lesions and pathologic identification of sessile serrated adenomas/polyps vary on the basis of center. (2014) (132)
Fecal occult blood screening for colorectal cancer. Is mortality reduced by chance selection for screening colonoscopy? (1994) (124)
Colon cancer screening in 2005: status and challenges. (2005) (121)
Sensationalism in the media: when scientists and journalists may be complicit collaborators. (2001) (118)
AGA future trends report: CT colonography. (2004) (117)
Transforming Epidemiology for 21st Century Medicine and Public Health (2013) (116)
Pragmatic classification of superficial neoplastic colorectal lesions. (2009) (112)
Biomarker studies: a call for a comprehensive biomarker study registry (2011) (107)
Colonoscopic surveillance after polypectomy: considerations of cost effectiveness. (1991) (101)
A quantitative assessment of pre-dental antibiotic prophylaxis for patients with mitral-valve prolapse. (1984) (100)
Clinical practice. Screening for colorectal cancer. (2002) (99)
Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. (2013) (98)
Colon cancer in ulcerative colitis. (1988) (89)
New American Cancer Society process for creating trustworthy cancer screening guidelines. (2011) (87)
Aortic stenosis, idiopathic gastrointestinal bleeding, and angiodysplasia: is there an association? A methodologic critique of the literature. (1988) (87)
Adequacy of reporting race/ethnicity in clinical trials in areas of health disparities. (2003) (86)
How Much Does Colonoscopy Reduce Colon Cancer Mortality? (2009) (85)
Rationale and design of the European Polyp Surveillance (EPoS) trials (2016) (84)
Gastroesophageal reflux, Barrett esophagus, and esophageal cancer: clinical applications. (2002) (84)
Data Sources for Measuring Colorectal Endoscopy Use Among Medicare Enrollees (2007) (80)
Colorectal Cancer Incidence and Mortality After Removal of Adenomas During Screening Colonoscopies. (2020) (79)
Breaking a Vicious Cycle (2013) (78)
Effectiveness and patient satisfaction with screening flexible sigmoidoscopy performed by registered nurses. (1999) (77)
Metachronous colon cancer in persons who have had a large adenomatous polyp. (1996) (73)
Mechanisms of glove tears and sharp injuries among surgical personnel. (1991) (71)
Developing Molecular Biomarkers for Cancer (2003) (70)
Small adenomas detected during fecal occult blood test screening for colorectal cancer. The impact of serendipity. (1990) (70)
Outcome of acute cholecystitis in patients with diabetes mellitus. (1987) (69)
Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. (2007) (68)
Early detection of prostate cancer. Serendipity strikes again. (1997) (67)
Personal genomics: information can be harmful (2010) (67)
Lessons from the Mammography Screening Controversy: Can We Improve the Debate? (1997) (65)
Screening Colonoscopy in the US: Attitudes and Practices of Primary Care Physicians (2012) (62)
Is Bowen's disease a predictor for the development of internal malignancy? A methodological critique of the literature. (1987) (59)
Integrated Proteomic and Glycoproteomic Characterization of Human High-Grade Serous Ovarian Carcinoma. (2020) (58)
Screening for colorectal cancer with the fecal occult blood test: a background paper. American College of Physicians. (1997) (58)
Protein-based multiplex assays: mock presubmissions to the US Food and Drug Administration. (2010) (58)
Suggested technique for fecal occult blood testing and interpretation in colorectal cancer screening. American College of Physicians. (1997) (57)
Terminal hepatic failure following a small dose of sulfamethoxazole-trimethoprim. (1981) (56)
Analytical validation of protein-based multiplex assays: a workshop report by the NCI-FDA interagency oncology task force on molecular diagnostics. (2010) (54)
The irritable bowel syndrome: Toward optimal design of controlled treatment trials (1993) (53)
Challenges and opportunities in evaluating diagnostic tests. (2002) (51)
Risk for Colorectal Cancer in Persons With a Family History of Adenomatous Polyps (2012) (51)
How can polygenic inheritance be used in population screening for common diseases? (2013) (51)
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration (2011) (50)
Recommendations for Post-Polypectomy Surveillance in Community Practice (2011) (50)
Derivation and Validation of a Scoring System to Stratify Risk for Advanced Colorectal Neoplasia in Asymptomatic Adults: A Cross-sectional Study (2015) (49)
Increasing colorectal cancer screening among individuals in the carpentry trade: test of risk communication interventions. (2005) (48)
Interpretations of 'appropriate' minority inclusion in clinical research. (2004) (46)
Licensure, use, and training of paramedical personnel to perform screening flexible sigmoidoscopy. (1999) (46)
Management of patients with symptomatic gallstones: a quantitative analysis. (1990) (46)
Editorial: Is decision analysis useful in clinical medicine? (1976) (43)
Consensus statement on therapeutic endoscopy and bleeding ulcers. Consensus Development Panel. (1990) (42)
Virtual colonoscopy--what it can do vs what it will do. (2004) (42)
Evaluation of Claims, Medical Records, and Self-report for Measuring Fecal Occult Blood Testing among Medicare Enrollees in Fee for Service (2008) (38)
Tailoring colorectal cancer screening by considering risk of advanced proximal neoplasia. (2012) (38)
Accuracy of administrative data in trauma. (1999) (37)
Treatment of gallstones. (1993) (37)
CON: Immediate Colonoscopy Is Not Necessary in Patients Who Have Polyps Smaller Than 1 cm on Computed Tomographic Colonography (2005) (37)
Issues in cholecystectomy and management of duct stones. (1994) (34)
Cancer. Developing molecular biomarkers for cancer. (2003) (33)
Derivation and Validation of a Scoring System to Stratify Risk for Advanced Colorectal Neoplasia in Asymptomatic Adults (2015) (33)
Guidelines for the Treatment of Gallstones (1993) (32)
Clinical Practice Guidelines for Colorectal Cancer Screening: New Recommendations and New Challenges. (2016) (31)
Cancer in inflammatory bowel disease: how serious is the problem and what should be done about it? (1983) (29)
Improving the fecal occult-blood test. (1996) (28)
Accuracy of self-reports of fecal occult blood tests and test results among individuals in the carpentry trade. (2003) (26)
Proteomics research to discover markers: what can we learn from Netflix? (2010) (26)
Lessons from the UK sigmoidoscopy screening trial (2002) (26)
Risk of Advanced Neoplasia Using the National Cancer Institute’s Colorectal Cancer Risk Assessment Tool (2017) (26)
The process to discover and develop biomarkers for cancer: a work in progress. (2008) (25)
Gene-expression signatures in breast cancer. (2003) (25)
Promises and limitations of biomarkers. (2009) (24)
Have we oversold colonoscopy? (2005) (23)
Evaluating discovery-based research: when biologic reasoning cannot work. (2004) (23)
Meeting report from the joint IARC–NCI international cancer seminar series: a focus on colorectal cancer (2019) (23)
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration (2011) (22)
Leveraging biospecimen resources for discovery or validation of markers for early cancer detection. (2015) (21)
Achieving quality in flexible sigmoidoscopy screening for colorectal cancer. (2001) (21)
What can we conclude from the randomized controlled trials of fecal occult blood test screening? (1998) (21)
Assessment of Serum Proteomics to Detect Large Colon Adenomas (2008) (21)
Screening colonoscopy in balance. Issues of implementation. (2002) (20)
Is Helicobacter pylori a cause of duodenal ulcer? A methodologic critique of current evidence. (1991) (20)
Modifying attributions of colorectal cancer risk. (2004) (20)
Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing. (2000) (19)
Comparison of a brush‐sampling fecal immunochemical test for hemoglobin with a sensitive guaiac‐based fecal occult blood test in detection of colorectal neoplasia (2007) (19)
Corrigendum: Multi-site assessment of the precision and reproducibility of multiple reaction monitoring–based measurements of proteins in plasma (2009) (18)
Is colchicine effective therapy for cirrhosis? (1988) (18)
Implications of New Colorectal Cancer Screening Technologies for Primary Care Practice (2008) (17)
Understanding differences in the guidelines for colorectal cancer screening. (2010) (16)
To Biopsy or Not to Biopsy in suspected Herpes Simplex Encephalitis (1988) (16)
Exposure rates to patients' blood for surgical personnel. (1993) (16)
Discovery-based research and fishing. (2003) (15)
Effectiveness and economic impact of screening for colorectal cancer by mass fecal occult blood testing (2000) (14)
What is the role of iFOBT in screening for colorectal cancer? (2007) (13)
Prospective Clinical Validation of an Assay for Methylated SEPT9 DNA in Human Plasma as a Colorectal Cancer Screening Tool in Average Risk Men and Women ≥50 Years (2010) (13)
Economic impact of surveillance. (1999) (13)
Meeting report from the joint IARC-NCI international cancer seminar series: a focus on colorectal cancer. (2019) (12)
The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening. (2000) (11)
The practices and attitudes of primary care nurse practitioners and physician assistants with respect to colorectal cancer screening (2000) (11)
Why Hasn't Genomic Testing Changed the Landscape in Clinical Oncology? (2012) (11)
Guidelines for guidelines: measuring trustworthiness. (2013) (11)
Using colonoscopy to screen for colorectal cancer. (1994) (11)
Why are cholecystectomy rates increasing? (1995) (11)
Cultivating Cohort Studies for Observational Translational Research (2013) (10)
Research opportunity at the interface of molecular biology and clinical epidemiology (2002) (10)
Evaluating risk: a primer for gastroenterologists. (1995) (10)
Derivation and validation of a predictive model for advanced colorectal neoplasia in asymptomatic adults (2020) (9)
Validation of Biomarker Panels for Ovarian Cancer A Framework for Evaluating Biomarkers for Early Detection : Updated (2011) (9)
Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and Accountability (2017) (9)
Screening for colorectal cancer [1] (multiple letters) (2000) (9)
The effect of fecal occult-blood screening on the incidence of colorectal cancer. (2001) (9)
Multitarget stool DNA testing for colorectal-cancer screening. (2014) (9)
On the sensitivity of fecal occult blood test screening for colorectal cancer. (1997) (8)
Gastroesophageal Reflux, Barrett Esophagus, and Esophageal Cancer (2017) (8)
Workgroup III: facilitating screening for colorectal cancer: quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002). (2005) (8)
Mortality From Postscreening (Interval) Colorectal Cancers Is Comparable to That From Cancer in Unscreened Patients-A Randomized Sigmoidoscopy Trial. (2018) (7)
Predicting risk for the appearance of melanoma. (2006) (7)
Cross-Model Comparisons to Improve the Value of Modeling (2011) (7)
Overstating the Evidence for Lung Cancer Screening (2007) (7)
The case for colorectal cancer screening. (1994) (6)
Can endoscopy protect against colorectal cancer? An RCT (2010) (6)
Screening for Colorectal Neoplasia. (2017) (5)
RESPONSE: Re: Lessons from Controversy: Ovarian Cancer Screening and Serum Proteomics (2005) (5)
Sigmoidoscopy costs and the limits of altruism. (1999) (5)
Strengthening the reporting of Genetic RIsk Prediction Studies (GRIPS): explanation and elaboration. (2011) (4)
SCREENING FOR COLORECTAL CANCER : WHICH TEST IS BEST ? AUTHORS' REPLY (1994) (4)
Strengthening the reporting of genetic risk prediction studies (GRIPS): explanation and elaboration (2011) (4)
Tu1072 Predicting Advanced Proximal Neoplasia in Asymptomatic Adults Without Knowing Distal Colorectal Findings: A New Scoring System With High Discrimination (2015) (4)
Fecal DNA tests for colorectal cancer. (2002) (4)
Treatment of Gallstones (1912) (3)
760 A Risk Index to Stratify the Risk of Advanced Colorectal Neoplasia in Asymptomatic Adults (2013) (3)
Predictive Value Tools as an Aid in Chemopreventive Agent Development. (2013) (3)
Evaluating a new cancer screening blood test: Unintended consequences and the need for clarity in policy-making. (2020) (3)
Hepatitis B vaccination. Three decision strategies for the individual. (1984) (3)
Carcinoma or dysplasia in Crohn's disease. (1982) (3)
Colon cancer screening models: lessons and challenges. (2013) (3)
What is the effect of more sensitive diagnostic technology? (2014) (3)
Using Models to Make Policy (2011) (3)
Development of trustworthy practice guidelines--reply. (2013) (2)
Five-Year Risk of Colorectal Neoplasia among Persons with No Neoplasia on Baseline Screening Colonoscopy: Final Results (2006) (2)
More on gastric lesions, aspirin, and rheumatic disease (1980) (2)
Natural history of cholelithiasis (1985) (2)
Real-time ultrasonography in the diagnosis of gallbladder disease (1981) (2)
A new clinical index to stratify risk for advanced proximal neoplasia in asymptomatic adults (2001) (2)
Flexible sigmoidoscopy to prevent colorectal cancer (2010) (2)
Surveillance colonoscopy for colorectal polyps: Recommendations by US gastroenterologists and surgeons (2003) (1)
International cancer seminars:a focus on colorectal cancer (2019) (1)
Computed tomographic colonography without cathartic preparation performed well in detecting colorectal polyps (2005) (1)
Prospective clinical validation of an assay for methylated SEPT9 DNA for use in detection of colorectal cancer in human plasma from average risk men and women over the age of 50 (2010) (1)
Why classify inflammatory bowel disease? (1982) (1)
Effect of a prior colorectal screening or diagnostic test on findings at screening colonoscopy (2001) (1)
Long-term natural history of silent gallstones: implications for secondary prevention (1984) (1)
Decision analysis for the practicing gastroenterologist. 3. A primer in reading a decision analysis article. (1985) (1)
Lactose intolerance and recurrent abdominal pain in childhood (1980) (1)
A Bad Tumor Marker Is as Bad as a Bad Drug: Applying Scientific Principles to Tumor Biomarker Research (2012) (1)
Guarding the Integrity of Medical Ethics (2016) (1)
Institutional Responsibility and the Flawed Genomic Biomarkers at Duke University: A Missed Opportunity for Transparency and Accountability (2016) (1)
New scoring systems for predicting advanced proximal neoplasia in asymptomatic adults with or without knowing distal colorectal findings: a prospective, cross-sectional study (2021) (1)
Colorectal cancer screening in North Carolina. Community clinicians' perspectives. (2001) (1)
Yield of screening colonoscopy in persons aged 40 to 49 years (2000) (1)
Helicobacter pylori and duodenal ulcer, gastric cancer, and nonulcer dyspepsia: A review (1994) (1)
Epidemiologic methods and methodologic vigilance (1988) (0)
Three Decision Strategies for the Individual (1984) (0)
710 Risk of Advanced Proximal Neoplasia (APN) Among 10,124 Index Screening Colonoscopies: Implications for Colorectal Cancer (CRC) Screening (2009) (0)
Colorectal cancer screening: clinical guidelines and rationale. (1997) (0)
Antibiotic prophylaxis for peritonitis in cirrhosis (1991) (0)
Screening for Colorectal Cancer in Asymptomatic Average-Risk Adults (2020) (0)
Glove Tears and Sharp Injuries in Surgical Personnel-Reply (1992) (0)
Gallbladder Stones (Gallenblasen steine). Karger, Munich, F.R.G. (1987), By C. Wolpers. 196 pp. ISBN: 3-8055-4522-3 (1988) (0)
Reply to Young (2005) (0)
Challenges in evaluating molecular markers as surrogates for cancer prevention (2006) (0)
Colon cancer screening: January 2002 - Live event (2002) (0)
Helicobacter pylori infection increased the risk for gastric carcinoma (1992) (0)
VARIANCE AND DISSENT Response to commentary (2007) (0)
Sigmoidoscopy costs and the limits of altruism (multiple letters) [1] (2000) (0)
DECISION ANALYSIS WHEN RISKS CHANGE WITH TIME. (1983) (0)
Colon cancer screening (2018) (0)
Pharyngitis and decision analysis. (1977) (0)
Phenotypic features effectively stratify risk for advanced colorectal neoplasia in asymptomatic adults (2015) (0)
Is Gallbladder Function a Predictor of Outcome? (1994) (0)
Q What is the diagnostic performance of low dose multidetector computed tomographic colonography (CTC) without bowel cathartic preparation compared with optical colonoscopy for detection of colonic polyps (2005) (0)
Is Prevention Better Than Cure (1986) (0)
Norfloxacin reduced spontaneous bacterial peritonitis in hospitalized patients with cirrhosis (1991) (0)
Hepatitis B Vaccination. Three Decision Strategies for the Individual (1985) (0)
Prizes for Student Research in Medical Decision Making (1982) (0)
Cancer Epidemiology in the 21 st Century Transforming Epidemiology for 21 st Century Medicine and Public Health (2013) (0)
Does UGI endoscopy affect decision making (1980) (0)
Book Review : Biomedical Bestiary: An Epidemiologic Guide to Flaws and Fallacies in the Medical Literature Max Michael, III, Thomas W. Boyce, and Allen J. Wilcox. 161 pp. Boston: Little, Brown and Co., 1984. $12.95 (1985) (0)
Reader response to colonoscopy versus sigmoidoscopy. (2006) (0)
The Contribution of Non-Physician Health Workers to the Delivery of Primary Care. (1971) (0)
Dating gallstones (0)
Counting Advanced Pre-Cancerous Lesions as True Positives When Determining Colorectal Cancer Screening Test Specificity. (2022) (0)
S8. Promises and limitations of biomarkers (2008) (0)
EDITORIALS On the Sensitivity of Fecal Occult Blood Test Screening for Colorectal Cancer (1997) (0)
Review: Helicobacter pylori is associated with gastritis, duodenal ulcer, and gastric cancer (1994) (0)
Helicobacter pylori infection increased the risk for gastric carcinoma among Japanese American men (1992) (0)
Improving the Clinical Validity of Biomarker Research in Cancer Detection (2017) (0)
Fecal DNA testing: The future of colorectal cancer screening? (2005) (0)
Biomedical bestiary: An epidemiologic guide to flaws and fallacies in the medical literature (1985) (0)
In adults, sigmoidoscopy screening invitation reduced CRC incidence and related mortality at 15 y (2023) (0)
Iconographies supplémentaires de l'article : Achieving quality in flexible sigmoidoscopy screening for colorectal cancer (2011) (0)
Risk for Advanced Colorectal Neoplasia in Asymptomatic Adults is Effectively Stratified by Phenotypic Features: Presidential Poster: 2126 (2013) (0)
Effect of ehrlich ascites fluid on granuloma formation to schistosoma mansoni eggs in the lungs of mice. Abstr. (1970) (0)
More on radionuclide scanning in the diagnosis of acute cholecystitis (1980) (0)
Erratum: Workgroup III: Facilitating screening for colorectal cancer: Quality assurance and evaluation. UICC International Workshop on Facilitating Screening for Colorectal Cancer, Oslo, Norway (29 and 30 June 2002) (Annals of Oncology (2005) vol. 16 (34-37)) (2005) (0)
Sigmoidoscopy costs and the limits of altruism: The reply (2000) (0)
Endoscopic ultrasonography was sensitive and specific in detecting choledocholithiasis (1996) (0)
Colorectal Cancer Outcomes in Veterans With Non-advanced Neoplasia: 2017 Category Award (Colorectal Cancer Prevention): 209 (2017) (0)
790 Can the NCI's Risk Assessment Tool for Future Risk of Colorectal Cancer Be Used to Estimate Current Risk for Advanced Neoplasia? (2012) (0)
Personal Profiles (2009) (0)
Folate supplementation in ulcerative colitis. (1990) (0)
Abstract IA07: Using genetic information in screening and prevention: Perspective of clinicians and policy-makers (2017) (0)
222 Estimating predictive values of short-term morphologic assays of cancer chemoprevention for efficacy in animal tumor assays (2014) (0)
1131 COLORECTAL CANCER MORTALITY IN VETERANS WITH LOW-RISK ADENOMAS (LRA) AND THE EFFECT OF SUBSEQUENT COLONOSCOPY (2020) (0)
A Scoring System for Predicting the Risk of Advanced Proximal Neoplasia in Asymptomatic Adults: 2035 (2014) (0)
225 A Risk Stratification Strategy for Colorectal Cancer Screening: Sequential Application of Two Clinical Prediction Rules (2014) (0)
Risk of Colorectal Cancer (CRC) in Persons with a Family History (Fhx) of Adenomatous Polyps: a Systematic Review (2008) (0)
GLOVE TEARS AND SHARP INJURIES IN SURGICAL PERSONEL. AUTHOR'S REPLIES (1992) (0)
Validation of a Risk Index for Advanced Proximal Colorectal Neoplasia in Asymptomatic Adults: 1481 (2009) (0)
Predicting risk for the appearance of melanoma. - eScholarship (2006) (0)
Screening for Colorectal Cancer: Which Test Is Best?-Reply (1994) (0)
Abstract B53: Predicting efficacy of chemopreventive agents in animal tumor assays by statistical modeling (2015) (0)
In adults, a single colonoscopy screening invitation vs. no invitation reduced CRC incidence at 10 y (2023) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Dr. David F. Ransohoff?

Dr. David F. Ransohoff is affiliated with the following schools: